TARS

SEC source: 0001405253-26-000005 · wk-form4_1773779217.xml · derivative · entry 2

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,040

Underlying: Common Stock · 8,020 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001405253-26-000005 · wk-form4_1773779217.xml · nonDerivative · entry 1

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,746

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · derivative · entry 5

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,574

Underlying: Common Stock · 5,524 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F7 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

F7 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · derivative · entry 4

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,040

Underlying: Common Stock · 8,020 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · derivative · entry 3

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,148

Underlying: Common Stock · 8,148 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · derivative · entry 2

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

SEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · nonDerivative · entry 1

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,536

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F2 · balance_after: Includes 497 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025.

SEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · derivative · entry 6

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,634

Underlying: Common Stock · 14,878 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F7 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

F7 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · derivative · entry 5

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,243

Underlying: Common Stock · 23,121 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · derivative · entry 4

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,975

Underlying: Common Stock · 16,975 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · derivative · entry 3

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

SEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,024

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001842190-26-000005 · wk-form4_1773778809.xml · derivative · entry 4

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,534

Underlying: Common Stock · 2,511 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001842190-26-000005 · wk-form4_1773778809.xml · nonDerivative · entry 1

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,452

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001841401-26-000003 · wk-form4_1773086812.xml · derivative · entry 2

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,161

Underlying: Common Stock · 17,161 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

SEC source: 0001841401-26-000003 · wk-form4_1773086812.xml · derivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,310

Underlying: Common Stock · 27,310 shares

Expires 2026-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001405253-26-000003 · wk-form4_1773086806.xml · derivative · entry 2

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,306

Underlying: Common Stock · 19,306 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

SEC source: 0001405253-26-000003 · wk-form4_1773086806.xml · derivative · entry 1

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,724

Underlying: Common Stock · 30,724 shares

Expires 2036-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001788542-26-000003 · wk-form4_1773086801.xml · derivative · entry 2

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,306

Underlying: Common Stock · 19,306 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

SEC source: 0001788542-26-000003 · wk-form4_1773086801.xml · derivative · entry 1

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,724

Underlying: Common Stock · 30,724 shares

Expires 2036-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001827584-26-000005 · wk-form4_1773086795.xml · derivative · entry 2

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,161

Underlying: Common Stock · 17,161 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

SEC source: 0001827584-26-000005 · wk-form4_1773086795.xml · derivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,310

Underlying: Common Stock · 27,310 shares

Expires 2036-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001839516-26-000005 · wk-form4_1773086790.xml · derivative · entry 2

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,161

Underlying: Common Stock · 17,161 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

SEC source: 0001839516-26-000005 · wk-form4_1773086790.xml · derivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,310

Underlying: Common Stock · 27,310 shares

Expires 2036-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001842190-26-000003 · wk-form4_1773086785.xml · derivative · entry 2

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,161

Underlying: Common Stock · 17,161 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

SEC source: 0001842190-26-000003 · wk-form4_1773086785.xml · derivative · entry 1

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,310

Underlying: Common Stock · 27,310 shares

Expires 2036-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001827672-26-000003 · wk-form4_1773086778.xml · derivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,776

Underlying: Common Stock · 60,776 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

SEC source: 0001827672-26-000003 · wk-form4_1773086778.xml · derivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,723

Underlying: Common Stock · 96,723 shares

Expires 2036-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001827584-26-000002 · wk-form4_1772744614.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,817

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001051578-26-000004 · wk-form4_1771623346.xml · derivative · entry 2

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,729

Underlying: Common Stock · 3,729 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001051578-26-000004 · wk-form4_1771623346.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,893

Underlying: Common Stock · 5,893 shares

Expires 2036-02-17

F1 · derivative.exercise_date: The option shares will vest in three equal annual installments on February 18th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001839516-26-000002 · wk-form4_1767733540.xml · nonDerivative · entry 4

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,393

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

F5 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $82.82 to $83.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001839516-26-000002 · wk-form4_1767733540.xml · nonDerivative · entry 3

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,286

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.68 to $82.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001839516-26-000002 · wk-form4_1767733540.xml · nonDerivative · entry 2

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,121

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.42 to $81.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001839516-26-000002 · wk-form4_1767733540.xml · nonDerivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,243

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $79.42 to $80.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001827672-25-000007 · wk-form4_1767129970.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 857,991

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024.

F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $83.14 to $84.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

SEC source: 0001827672-25-000007 · wk-form4_1767129970.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 858,548

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.89 to $82.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

SEC source: 0001842190-25-000003 · wk-form4_1766005632.xml · nonDerivative · entry 2

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,941

F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827584-25-000003 · wk-form4_1766092157.xml · nonDerivative · entry 2

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By daughter

Disclosed balance after: 475

F2 · kind: This transaction involved the Reporting Person's gift of 475 shares of common stock to his daughter who shares Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001827584-25-000003 · wk-form4_1766092157.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,183

F1 · balance_after: Includes 451 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.

SEC source: 0001839516-25-000003 · wk-form4_1766092136.xml · nonDerivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,958

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

SEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 5

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Link Family Enterprise, LP

Disclosed balance after: 0

F5 · kind: The sales were not effected by a sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F8 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.21 to $81.79. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.

SEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 4

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Link Family Enterprise, LP

Disclosed balance after: 4,766

F5 · kind: The sales were not effected by a sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.21 to $81.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.

SEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 3

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,832

F1 · kind: The sales were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $82.23 to $82.92. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,980

F1 · kind: The sales were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.21 to $82.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001228684-25-000005 · wk-form4_1766005663.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,286

F1 · kind: The sales were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.21 to $81.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001842190-25-000003 · wk-form4_1766005632.xml · derivative · entry 5

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,459

Underlying: Common Stock · 6,819 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSUs granted on November 4, 2024 in connection with the Reporting Person's appointment as Chief Medical Officer. 25% of the RSUs will vest on December 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on November 4, 2024 in connection with the Reporting Person's appointment as Chief Medical Officer. 25% of the RSUs will vest on December 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001842190-25-000003 · wk-form4_1766005632.xml · nonDerivative · entry 1

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,019

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F2 · balance_after: Since the date of the Reporting Person's last report, 9,506 shares previously owned by the Reporting Person's Spouse's Roth IRA were transferred to the Reporting Person's self-directed IRA and are now directly owned.

SEC source: 0002044770-26-000002 · wk-form4_1768437158.xml · derivative · entry 2

Goodrich Katherine · CIK 0002044770 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,467

Underlying: Common Stock · 2,233 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: The RSUs will vest in three equal installments on December 15th of 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in three equal installments on December 15th of 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0002044770-26-000002 · wk-form4_1768437158.xml · nonDerivative · entry 1

Goodrich Katherine · CIK 0002044770 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,233

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.